Surveying the Treatment Landscape: Therapeutic Advancements Affecting Treatment Decisions in AML
To continue, select another chapter from the Chapter List
Release Date: June 11, 2021
Expiration Date: June 11, 2022
Expected time to complete this activity as designed: 15 minutes
There are no fees for participating in or receiving credit for this online activity.
Join Dr. Eytan Stein as he explores the evolving treatment landscape for acute myeloid leukemia (AML). Topics to be discussed include new uses of hypomethylating agents and venetoclax, targeted therapies for specific mutations, and investigational low-intensity treatment combinations. Dr. Stein will also extrapolate on expanding concepts such as patient ‘fitness,’ measurable residual disease, and maintenance therapy for AML.
This activity is designed for multidisciplinary healthcare providers in the community setting, including hematologists, oncologists, pharmacists and other allied healthcare professionals who provide care to patients with acute myeloid leukemia.
Upon completion of this educational activity, participants should be able to:
- Outline the landscape of currently approved agents and combinations of agents in the treatment of newly diagnosed and relapsed/refractory AML which align to the individual needs of your patient
- Review ongoing clinical trials, including those of single agents and therapeutic combinations
Surveying the Treatment Landscape: Therapeutic Advancements Affecting Treatment Decisions in AML – Eytan M. Stein, MD
Instructions for Participation and Credit
This activity is eligible for credit through June 11, 2022. After this date, this activity will expire and no further credit will be awarded.
- Read the target audience, learning objectives, and faculty disclosures.
- You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
- Complete the educational content as designed.
- Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
- Complete the activity evaluation survey to provide feedback and information useful for future programming.
- Certificates for CME may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.
Eytan M. Stein, MD
Assistant Attending Physician
Director, Program for Drug Development in Leukemia
Leukemia Service, Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York
Dr. Eytan Stein received his medical degree from Northwestern University in Chicago, where he also completed his internal medicine residency. He then completed his fellowships in medicine at Weill Cornell Medical College, and in medical oncology and hematology at Memorial Sloan Kettering. Dr. Stein is an Assistant Attending Physician, Clinical Investigator, and Director of the Program for Drug Development in Leukemia on the Leukemia Service at Memorial Sloan Kettering Cancer Center.
Dr. Stein conducts novel, phase I clinical trials of compounds that target the genetic and epigenetic basis of myeloid malignancies. He led the clinical studies of the IDH2 inhibitor enasidenib and the IDH1 Inhibitor ivosidenib in patients with relapsed and refractory acute myeloid leukemia (AML) that led to FDA approval in 2017 and 2018. He also leads a variety of phase 1 clinical trials and serves as the lead investigator at Memorial Sloan Kettering for the Beat AML® Master Clinical Trial. Dr. Stein’scurrent research focuses on elucidating mechanisms of resistance to IDH inhibitors and the use of menin inhibitors in patients with MLL-rearranged acute leukemia. His work has been published in journals such as Nature, Nature Medicine, The New England Journal of Medicine, JAMA Oncology, Cancer Discovery, and Blood. In addition, he serves on the editorial boards of Blood and Leukemia and Lymphoma.
If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at firstname.lastname@example.org.
Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Bristol-Myers Squibb, Genentech, Helsinn Healthcare SA, and Jazz Pharmaceuticals.
©2021 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
MediCom Worldwide, Inc. designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 0.25 contact hours of Continuing Education Credit. Universal Activity Number: 827-0000-21-026-H01-P. Knowledge-based CPE activity.
In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.
International Pharmacy Preceptors and Canadian Pharmacists: If you are in need of e-Profile ID to participate in an ACPE approved activity, please contact NABP customer service for further assistance as special handling is necessary. NABP customer service can be reached at (847) 391-4406.
As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.
Dr. Eytan Stein has received honoraria related to formal advisory activities from and owns significant holdings in AbbVie Inc., Agios, Inc., Astellas Pharma US, Inc., Auron Therapeutics, Bristol-Myers Squibb Company, Celgene Corporation ‒ A Bristol-Myers Squibb Company, Genentech, Inc., Gilead, Janssen Pharmaceuticals, Inc., Syndax Pharmaceuticals, and Syros Pharmaceuticals, Inc.
Planning Committee Disclosures
The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, RN, MHA, Executive Director, Isabelle Vacher, Vice President of Educational Strategy, Scott J. Hershman, MD, FACEHP, CHCP, Educational Program Director, Lillian McVey, Medical Writer, and Andrea Mathis, Project Manager, have no relevant financial relationships.
Peer Reviewer Disclosure
In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.